MNK1 Inhibitors
1 drugsAbout MNK1
MNK1, or MAP kinase-interacting kinase 1, is a protein kinase regulating protein synthesis, a process critical for cell growth and proliferation.
While MNK1's involvement in cancer progression makes it a compelling target, there is currently no genetic evidence directly linking it to specific diseases.
The oncology target MNK1 is currently addressed by one FDA-approved drug, VIZIMPRO, a small molecule developed by Pfizer.
Top MNK1 Drugs
Pfizer is the only company with an approved drug targeting MNK1.
The limited competitive landscape presents an opportunity for new entrants to develop MNK1-targeting therapies.
MNK1 Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on MNK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 9 | 2 | 1 | 82% |
| Phase 2 | 12 | 6 | 1 | 5 | 86% |
| Phase 3 | 3 | 2 | 0 | 1 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on MNK1. A trial counts if an approved drug acting on MNK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.